Researchers say developing a vaccine for the Zika virus – suspected
of causing brain damage in babies – could take up to five years, as
health experts called for new incentives for drug companies. The Zika

outb

reak, which the World Health Organization says is
likely to spread
to all countries in the Americas except for Canada and Chile, follows
the Ebola epidemic in West Africa, which also caught health authorities
off guard. “We’ve got no drugs and we’ve got no vaccines. It’s a case of
deja vu because that’s exactly what we were saying with Ebola,” Trudie
Lang, a professor of global health at the University of Oxford, told
Reuters. “It’s really important to develop a vaccine as quickly as
possible.”
Large drugmakers’ investment in tropical disease vaccines with
uncertain commercial prospects has so far been patchy, but the pace of
the outbreak has demonstrated how quickly little-known diseases can
emerge as global threats. “We need to have some kind of a plan that
makes [companies] feel there is a sustainable solution and not just a
one-shot deal over and over again,” Francis Collins, director of the US
National Institutes of Health, said last week.

The Sao Paulo-based Butantan Institute, which is currently leading
the research charge on Zika, says it plans to develop a vaccine “in
record time”, although its director has warned this is likely to take
three to five years. British drugmaker GlaxoSmithKline also told Reuters
on Monday it was studying the feasibility of using its vaccine
technology on Zika, while France’s Sanofi said it was reviewing
possibilities.
About the Author
Unknown
Author & Editor
Has laoreet percipitur ad. Vide interesset in mei, no his legimus verterem. Et nostrum imperdiet appellantur usu, mnesarchum referrentur id vim.
0 comments:
Post a Comment